word count (max 250): 241 ABSTRACT HIV and methamphetamine (MA) use disorder are commonly comorbid and individuallyassociated with adverse health consequences, including frailty; however, less is known about the combined effects of both conditions. The current cross-sectional study examined how HIV and lifetime MA use disorder relate to frailty, and explored associations between frailty and relevant clinical outcomes (i.e., neurocognitive and everyday functioning). Participants were categorized into three groups based on HIV status and lifetime MA diagnosis: HIV+/MA+ (n=43), HIV+/MA-(n=75), and HIV-/MA-(n=92). A frailty index score (representing proportion of accumulated multisystem deficits) was calculated from 27 medical and psychiatric deficits. Multiple regression was used to examine frailty index score by HIV/MA group. Additional multiple regression models examined the interaction between frailty and HIV/MA group on cognitive and everyday functioning.
INTRODUCTION
Methamphetamine (MA) is a highly addictive psychostimulant that can detrimentally impact neurocognition, real-world functioning, and medical outcomes [1] [2] [3] . MA misuse is particularly common among persons living with HIV (PLWH) and represents a major obstacle for public health efforts aimed at reducing the prevalence and severity of HIV 4, 5 . Chronic MA misuse not only enhances risk of HIV transmission, through needlesharing and unprotected sex 6, 7 , but can also exacerbate HIV disease burden by disrupting antiretroviral therapy (ART) efficacy and adherence 8 . Consequently, a myriad of clinical complications can arise from comorbid HIV disease and MA use disorders (HIV+/MA+).
It has been widely documented that MA and HIV independently inflict neuropathophysiological damage, with downstream decrements in neurocognitive and everyday functioning abilities [9] [10] [11] . Although less well studied, there is also evidence to suggest that additive neurotoxic effects of MA and HIV exist and operate via the convergence of MA-and HIV-related mechanisms of neural injury to preferentially damage frontostriatal regions 12, 13 . The coupling of MA misuse with HIV is characterized by neurocognitive deficits in executive functions, learning and memory, and motor skills [14] [15] [16] , which can translate to impairments in real-world daily functioning. These challenges in everyday functioning typically reflect high-stakes outcomes such as unemployment, dependence in instrumental activities of daily living (IADLs), and poor antiretroviral therapy (ART) adherence 17, 18 . Recent studies highlight an additive deleterious effect on everyday functioning such that HIV+/MA+ individuals exhibit the highest rates of IADL dependence compared to singly-affected groups (i.e., HIV-/MA+ and HIV+/MA-) 19 . Given the severity of impairments associated with MA misuse, a greater understanding of mechanisms underlying MA-associated neurobehavioral dysfunction is needed.
Frailty is one mechanism that may explain the detrimental effect of HIV+/MA+ on neurobehavioral impairment and has not been previously examined in this population. The construct of frailty, which first emerged through geriatric research, is conceptualized as vulnerability to multisystem damage and is most commonly used to predict risk for adverse health outcomes 20, 21 . There are several different approaches to operationalizing AIDS Research and Human Retroviruses Frailty in Comorbid HIV and Lifetime Methamphetamine Use Disorder: Associations with Neurocognitive and Everyday Functioning (DOI: 10.1089/AID.2019.0062) This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. frailty, including as an index representing the accumulation of multisystem health deficits (e.g., diabetes, chronic inflammation, anemia) associated with the erosion of homeostatic processes 22, 23 . One gerontological model for the role of frailty in neurocognition details a complex environment in which the gradual draining of physiological reserve dynamically interacts with psychosocial and functional factors to promote neurocognitive decline 24 .
Given the extensive evidence that PLWH are at risk for the acquisition of multiple comorbidities potentially reflective of an accelerated aging process 25 , frailty indices have been developed for PLWH across the lifespan and are predictive of mortality independent of markers of HIV disease burden 26, 27 .
Although the relationship between frailty and MA misuse is poorly characterized, MA misuse is linked to widespread toxicity of multiple organ systems (e.g., cardiovascular, renal, pulmonary) and enhances risk for mortality and multimorbidity 28, 29 . Furthermore, models of cellular senescence provide support that the physiological dysregulation caused by MA exposure may also reflect accelerated biological aging 30 . Indications that MA and HIV independently diminish the capacity to respond to physiological stressors, coupled with gerontological evidence linking frailty to incident neurocognitive decline 31-33 , necessitates the examination of frailty in the context of neurocognitive and everyday functioning among HIV+/MA+ persons.
An understanding of the temporal trends concerning MA misuse, frailty, and neurobehavioral impairment is critical for modeling their relationship. Although younger PLWH are more likely to actively use MA than older PLWH 34, 35 , older PLWH are more likely to exhibit frailty due to the strong relationship between frailty and age 20, 22 . Thus, we aimed to study the lasting effects of past MA use disorder on frailty among middle-aged to older PLWH. Thus, the current study examined differences in frailty across three groups: a group with comorbid HIV and lifetime MA use disorder [HIV+/MA+], an HIV+/MA-group, and an HIV-/MA-control group, and explored relationships between frailty and neurocognitive and everyday functioning among the three groups. We hypothesized that the comorbid HIV+/MA+ group would demonstrate the highest frailty compared to the other two groups. We also hypothesized that frailty would be negatively associated with
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MATERIALS AND METHODS

Participants
Participants consisted of 118 HIV-positive (HIV+) and 92 HIV-negative (HIV-) adults, aged 35 to 65 (M=50.8, SD=7.97), enrolled in the five-year Multi-Dimensional Successful Aging among HIV-Infected Adults study conducted at the University of California, San Diego (UCSD) 36, 37 . The current study represents a secondary analysis on available MA use data; thus, participants were not specifically recruited by lifetime MA status. Baseline data were included in this analysis. Study exclusion criteria were diagnosis of a psychotic disorder, presence of a neurological condition known to impact neurocognitive functioning (e.g., stroke), and positive urine toxicology for alcohol or drugs (excluding marijuana) on the day of testing. The study protocol was approved by the UCSD Institutional Review Board. Participants provided written, informed consent.
Measures
Psychiatric Assessment
The Composite International Diagnostic Interview (CIDI, v2.1) World Health 38 was administered to assess for presence of current and lifetime (occurring >12 months ago) substance use and mood disorders (e.g., major depressive disorder, MDD) based on the Diagnostic and Statistical Manual of Mental Disorders 39 . For this analysis, participants were categorized into three groups based on HIV status and lifetime methamphetamine (MA) abuse or dependence diagnosis: HIV+/MA+ (n=43); HIV+/MA-(n=75); and HIV-/MA-(n=92). No HIV-participants met criteria for lifetime MA use disorder in our available sample; therefore, our analysis is confined to the three groups identified above. Within the HIV+/MA+ group, 37 met criteria for lifetime MA dependence and 6 met criteria for lifetime MA abuse. No individuals in this sample met criteria for a current MA use disorder.
Neuromedical Assessment
Study participants completed a standardized medical history interview, which assessed for the presence of medical comorbidities (e.g., hyperlipidemia; diabetes This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. mellitus) using a combination of self-report and laboratory measurements; structured neurological and medical evaluation; and collection of blood and urine samples. All participants were screened for HIV infection using a fingerstick test (Medmira, Nova Scotia, Canada) and confirmed with an Abbott RealTime HIV-1 test (Abbott Laboratories, Illinois, USA) or by submitting specimens to a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (ARUP Laboratories, Utah, USA) for HIV-1 viral load quantitation.
Additional HIV characterization included AIDS status, plasma viral load, CD4+ T-cell counts (nadir and current), estimated duration of HIV disease, and current antiretroviral therapy (ART) regimen.
Frailty Assessment
Based on previously established methods 26, 27 , the frailty index was calculated as the proportion of health deficits from a group of 27 health variables, including markers of general health and comorbidities (Table 1) . Thus, frailty index scores have a possible range from 0 (no deficits) to 1 (all 27 deficits).
Each variable within the frailty index was dichotomized as "1", when a deficit was present, and "0", when absent, based on criteria displayed in Table 1 . The 27 selected variables were chosen based on all available neuromedical and neuropsychiatric data from the parent study that were consistent with variables included in previous frailty indexes 26, 27 . Additionally, following published guidelines for creating a frailty index 23 , we excluded factors that: 1) had greater than 5% missing data (i.e., greater than 10 missing cases in this sample), and 2) had less than 1% of participants meeting criteria for the deficit (i.e., fewer than 2 cases in this sample). Factors not included in the index due to having greater than 5% missing data in our sample included hemoglobin A1C and fasting insulin level. Factors not included in the index due to insufficient number of participants (<1%) meeting criteria for the deficit included abnormal sodium, albumin, and phosphorous levels.
Neurocognitive Assessment
Participants completed a standardized battery of neuropsychological tests to evaluate neurocognitive functioning. The battery assesses seven neurocognitive domains This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. commonly affected by HIV, i.e., verbal fluency, working memory, processing speed, verbal and visual learning and delayed recall, executive functioning, and motor skills 10 . Raw test scores were converted to T-scores (M=50; SD=10) adjusted to correct for age, gender, education, and race/ethnicity [40] [41] [42] . T-scores were averaged in each domain to obtain domain T-scores, and all test T-scores were averaged to obtain a Global T-score.
Everyday Functioning Assessment
In order to determine dependence in instrumental activities of daily living (IADL), participants completed a modified version of the Lawton and Brody ADL questionnaire 43 .
This self-report questionnaire queried 11 IADL domains (e.g., managing finances and managing medications) and asked participants to rate their current and highest levels of functioning. Participants were categorized as IADL dependent if they reported a decline or need for assistance in 2 IADL domains, regardless of whether the difficulties were attributed to cognitive or physical factors. This methodology has previously been validated in a normative sample 43 , and it has been shown to be associated with objective measures of functional loss in persons with HIV and/or MA use disorders 44, 45 .
Statistical Analyses
To compare HIV/MA groups on demographic, clinical, and primary outcome variables, one-way analysis of variance (ANOVA) was used. To follow up on significant omnibus results, pair-wise comparisons were examined using Tukey's H.S.D. (α = 0.05) for continuous outcomes or Bonferroni-adjustments (α = 0.05/3 = 0.0167) for dichotomous outcomes. Next, a multiple regression model was used to examine group differences in frailty, covarying for demographic and clinical factors that differed between groups.
Pearson correlations were used to explore associations between frailty index score and specific MA use disorder characteristics. Last, multiple linear and logistic regressions were used to examine the interactions between frailty and HIV/MA group on global neurocognitive T-score and IADL dependence. Due to potential lack of power to find significant interaction effects, exploratory group-stratified analyses were conducted examining the relationships of frailty index score to global neurocognitive T-score and IADL dependence within each HIV/MA group. Pearson r correlations were also used to examine relationships between frailty and domain-specific neurocognitive functioning within the HIV+/MA+ group.
RESULTS
Participant Characteristics
Demographic and clinical characteristics for each HIV/MA group are presented in Table 2 . The HIV+/MA-group had the fewest non-Hispanic Whites, compared to the HIV+/MA+ and HIV-/MA-groups (p<.001), and the HIV+/MA+ group had fewer years of education compared to the other two groups (p<.001). PLWH (regardless of MA status) were more likely to be unemployed than persons without HIV (p<.001). Regarding neuropsychiatric characteristics, both HIV+ groups were more likely to have current and lifetime major depressive disorder (MDD) than the HIV-/MA-group (ps<.001). The HIV+/MA+ group had the highest proportion of other (non-methamphetamine) lifetime substance use disorders (SUD) (p<.001). Regarding HIV disease severity, both HIV+ groups were comparable with fairly well-controlled HIV (ps>.05). Regarding MA use disorder characteristics in the HIV+/MA+ group, participants reported meeting criteria for an MA use disorder for the first time at 34 years of age on average (SD=10.1), and most recently met criteria for an MA use disorder at 43 years of age on average (SD=8.7).
Frailty, Neurocognition, and Everyday Functioning across HIV/MA Groups
Frailty index scores, neurocognitive impairment rates and T-scores, and IADL dependence rates for each group are displayed in Table 3 . In univariable analyses, frailty index score differed between all groups such that the comorbid HIV+/MA+ group had a higher mean frailty index score than the HIV+/MA-group, and the HIV+/MA-group had a higher mean frailty index score than the control group (p<.001; Figure 1 ). See This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. neurocognitive functioning. Last, a stair-step pattern of everyday functioning by group was observed, such that the HIV+/MA+ group displayed the highest rate of IADL dependence, followed by the HIV+/MA-group, and then the control group (p<.001).
Next, a multiple linear regression analysis was conducted to further explore the differences in frailty index score across groups, covarying for specified demographic and clinical characteristics. Covariates included age (to account for the known positive relationship between frailty and age) and any characteristic that differed between groups that were not included in the creation of the frailty index: race/ethnicity, years of education, and lifetime other (non-methamphetamine) SUD. Of note, we collapsed all nonmethamphetamine SUDs into one representative variable to seek parsimony in the regression models. Results of the multiple linear regression revealed that HIV/MA group membership was significantly associated with frailty index score, such that both the HIV-/MA-(b=-0.13; p<.001) and HIV+/MA-(b=-0.06; p=.007) groups had significantly lower frailty index scores than the HIV+/MA+ group (Table 4 ).
We also examined relationships between frailty and MA use disorder characteristics. Frailty index score was not significantly related to age at which participants first met criteria for MA use disorder (r=.08, p=.67), age at which participants most recently met criteria for MA use disorder (r=.08, p=.67), or years since last MA use disorder (r=. 20, p=.26) .
Relating Frailty Index Score to Neurocognitive and Everyday Functioning by HIV/MA
Group
The multiple linear regression examining the interaction between frailty and HIV/MA group on global neurocognitive T-score showed a main effect of frailty, such that higher frailty index score was associated with lower global T-score (b=-17.60; p=.02; Table   5 ). However, there was no main effect of HIV/MA group (ps>.05) and no interaction effect between frailty and group on global T-score (ps>.05). Exploratory follow-up analyses, however, showed that the HIV+/MA+ group had the strongest negative relationship between frailty index score and global T-score (r=-.28, p=.06), followed by HIV-/MA-(r=- This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. group revealed that frailty index score had the strongest negative association with executive functioning (r=-.34, p=.03) and working memory (r=-.33, p=.03), followed by processing speed (r=-. 25 Table 5 ). There was also no interaction between frailty index score and HIV/MA group (ps>.05). Exploratory follow-up analyses showed that the HIV+/MA+ group had the strongest positive relationship between frailty index score and In an effort to ensure that certain items within our frailty index were not redundant, and that results were not driven by psychosocial variables within the frailty index (i.e., unemployment and depression), we re-ran primary analyses with different variations of the frailty index. Specifically, we examined whether the stairstep effect of frailty by HIV/MA group held, and whether frailty index score still related to global neurocognition and IADL dependence. First, to ensure that items 2-5 (lipid panel values)
were not redundant with item 23 (hyperlipidemia) we created new frailty indexes removing either hyperlipidemia or all lipid panel values, and all results held. Next, to ensure that lifetime MDD was not redundant with current MDD, we created new frailty indexes removing either of these, and all results held. Finally, to ensure that psychosocial variables were not driving the relationship between HIV/MA group and frailty, we This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
DISCUSSION
Understanding the biological and functional consequences of HIV and lifetime MA use disorder is essential in order to provide optimal care for persons living with these conditions comorbidly. In support of our hypothesis, we found a stairstep pattern such that persons with comorbid HIV and MA use disorder had the highest frailty index scores, followed by HIV+/MA-, then HIV-/MA-. Although we did not find worse neurocognitive to those with HIV only, and that damage to these physiological systems remains detectable even when MA diagnosis is remote (i.e., more than one year prior to evaluation). Further understanding of the lasting effects of past MA misuse, with and without comorbid HIV infection, on frailty is warranted.
Notably, we found that frailty index score was not significantly related to MA use disorder characteristics (i.e., age at which participants first met criteria for MA use disorder, age at which participants most recently met criteria for MA use disorder, and years since last MA use disorder) within the HIV+/MA+ group. Although we do not have data to examine the relationship between specific MA use parameters (e.g., total lifetime grams of MA used) and frailty, our finding is consistent with prior research demonstrating that characteristics of MA use do not reliably predict neurocognitive functioning 51 .
Previous work indicates that such variability in the relationship between MA use and health outcomes may be explained by moderators on this relationship, including genetic susceptibility 52 .
Last, we examined relationships between frailty index score and neurocognitive and everyday functioning and explored whether these relationships differ across HIV/MA groups. Consistent with hypotheses, higher frailty index score was related to worse neurocognitive functioning and greater likelihood of IADL dependence. Notably, the interaction terms within multiple regression models were not significant, indicating that the associations of frailty to neurocognitive and everyday functioning did not significantly differ by HIV/MA group; however, our exploratory within-group analyses revealed that these relationships were strongest among participants with comorbid HIV and MA. These findings support the clinical relevance of our frailty index, particularly among HIV+/MA+ individuals, and suggest that it is comprised of components that represent physiological mechanisms underlying neurobehavioral functioning in this population. For example, the frailty index is hypothesized to capture erosion of homeostatic processes (e.g., metabolic factors, chronic inflammation) that likely result in adverse neurological outcomes (e.g., apoptosis, poor cerebral perfusion) 33 This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. memory may be especially affected by frailty, which is consistent with domains known to be impaired among individuals who are HIV+ and/or MA users [14] [15] [16] .
The current study is novel in its examination of the impact of HIV and lifetime MA on frailty; however, addressing its limitations is necessary to improve the methodology of future studies. First, there were no HIV-uninfected individuals who met criteria for a lifetime MA diagnosis in our sample, and thus, we cannot conclude whether our HIV+/MA+ group findings were simply reflective of an MA effect rather than a potential combined effect. Inclusion of a HIV-/MA+ group in future research is needed to uncover whether there may be an additive or interactive effect of HIV+/MA+ on frailty. We also did not collect data on specific MA or other substance use parameters (e.g., total grams used or total days of use) for our participants. Although MA use parameters do not reliably predict neurocognitive functioning 51 , future work may benefit from exploring dose-response relationships between MA and frailty. Next, we had a relatively limited sample size for HIV+/MA+ individuals. Although this limited our power to detect statistically significant interaction effects between frailty and HIV/MA group on neurocognitive and everyday functioning, we also utilized group-stratified analyses. Additionally, our frailty index, being comprised of 27 variables, contains slightly below published recommendations to include at least 30 variables to best capture relationships between health and mortality 23 ; however, less than 30 variables have been used in previous frailty indices 27 .
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